282 related articles for article (PubMed ID: 38396839)
1. Current Understanding of Immune Thrombocytopenia: A Review of Pathogenesis and Treatment Options.
Mititelu A; Onisâi MC; Roșca A; Vlădăreanu AM
Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396839
[TBL] [Abstract][Full Text] [Related]
2. Systemic lupus erythematosus-complicating immune thrombocytopenia: From pathogenesis to treatment.
Jiang Y; Cheng Y; Ma S; Li T; Chen Z; Zuo X; Zhang X
J Autoimmun; 2022 Oct; 132():102887. PubMed ID: 36030136
[TBL] [Abstract][Full Text] [Related]
3. Thrombopoietin receptor agonists for preparing adult patients with immune thrombocytopenia to splenectomy: results of a retrospective, observational GIMEMA study.
Zaja F; Barcellini W; Cantoni S; Carpenedo M; Caparrotti G; Carrai V; Di Renzo N; Santoro C; Di Nicola M; Veneri D; Simonetti F; Liberati AM; Ferla V; Paoloni F; Crea E; Volpetti S; Tuniz E; Fanin R
Am J Hematol; 2016 May; 91(5):E293-5. PubMed ID: 26910388
[TBL] [Abstract][Full Text] [Related]
4. Treatment patterns and outcomes of second-line rituximab and thrombopoietin receptor agonists in adult immune thrombocytopenia: A Canadian retrospective cohort study.
Podstawka J; Wall E; Bolster L; Patterson JM; Goodyear MD; Rydz N; Sun HL
Thromb Res; 2022 Dec; 220():5-11. PubMed ID: 36257098
[TBL] [Abstract][Full Text] [Related]
5. Complement activation negatively affects the platelet response to thrombopoietin receptor agonists in patients with immune thrombocytopenia: a prospective cohort study.
Åkesson A; Bussel JB; Martin M; Blom AM; Klintman J; Ghanima W; Zetterberg E; Garabet L
Platelets; 2023 Dec; 34(1):2159019. PubMed ID: 36636835
[TBL] [Abstract][Full Text] [Related]
6. Increased microvesicle-associated thrombin generation in patients with immune thrombocytopenia after initiation of thrombopoietin receptor agonists.
Garabet L; Ghanima W; Hellum M; Sandset PM; Bussel JB; Tran H; Henriksson CE
Platelets; 2020; 31(3):322-328. PubMed ID: 31280643
[TBL] [Abstract][Full Text] [Related]
7. Treatment patterns of thrombopoietin receptor agonists among adults with primary immune thrombocytopenia: A Korean nationwide population-based study.
Lee JY; Lee JH; Kim SA; Suh KJ; Kim JW; Kim SH; Lee JO; Kim JW; Kim YJ; Lee KW; Kim JH; Lee JS; Bang SM
Thromb Res; 2022 May; 213():114-118. PubMed ID: 35334441
[TBL] [Abstract][Full Text] [Related]
8. [Diagnostic approach and treatment of immune thrombocytopenia in adults].
Kolonić SO; Patekar MB; Milunović V
Acta Med Croatica; 2013 Mar; 67(1):3-11. PubMed ID: 24279250
[TBL] [Abstract][Full Text] [Related]
9. The burden of immune thrombocytopenia in adults: evaluation of the thrombopoietin receptor agonist romiplostim.
Deuson R; Danese M; Mathias SD; Schoonen M; Fryzek J
J Med Econ; 2012; 15(5):956-76. PubMed ID: 22533524
[TBL] [Abstract][Full Text] [Related]
10. Refractory primary immune thrombocytopenia (ITP): current clinical challenges and therapeutic perspectives.
Vianelli N; Auteri G; Buccisano F; Carrai V; Baldacci E; Clissa C; Bartoletti D; Giuffrida G; Magro D; Rivolti E; Esposito D; Podda GM; Palandri F
Ann Hematol; 2022 May; 101(5):963-978. PubMed ID: 35201417
[TBL] [Abstract][Full Text] [Related]
11. Positioning new treatments in the management of immune thrombocytopenia.
Arnold DM
Pediatr Blood Cancer; 2013; 60 Suppl 1(Suppl 1):S19-22. PubMed ID: 23109488
[TBL] [Abstract][Full Text] [Related]
12. Thrombopoietin Receptor Agonists in Children with Immune Thrombocytopenia: A New Therapeutic Era.
Lassandro G; Palladino V; Vecchio GCD; Palmieri VV; Corallo PC; Faienza MF; Giordano P
Endocr Metab Immune Disord Drug Targets; 2021; 21(3):397-406. PubMed ID: 32473624
[TBL] [Abstract][Full Text] [Related]
13. Recent advances in the mechanisms and treatment of immune thrombocytopenia.
Provan D; Semple JW
EBioMedicine; 2022 Feb; 76():103820. PubMed ID: 35074629
[TBL] [Abstract][Full Text] [Related]
14. Sustained remission of chronic immune thrombocytopenia after discontinuation of treatment with thrombopoietin-receptor agonists in adults.
Červinek L; Mayer J; Doubek M
Int J Hematol; 2015 Jul; 102(1):7-11. PubMed ID: 25833724
[TBL] [Abstract][Full Text] [Related]
15. Current and emerging treatments for immune thrombocytopenia.
Dou X; Yang R
Expert Rev Hematol; 2019 Sep; 12(9):723-732. PubMed ID: 31237783
[No Abstract] [Full Text] [Related]
16. European Delphi panel to build consensus on tapering and discontinuing thrombopoietin receptor agonists in immune thrombocytopenia.
Barlassina A; González-López TJ; Cooper N; Zaja F
Platelets; 2023 Dec; 34(1):2170999. PubMed ID: 36803535
[TBL] [Abstract][Full Text] [Related]
17. Emerging Therapies in Immune Thrombocytopenia.
Audia S; Bonnotte B
J Clin Med; 2021 Mar; 10(5):. PubMed ID: 33801294
[TBL] [Abstract][Full Text] [Related]
18. Current approaches for the diagnosis and management of immune thrombocytopenia.
Gafter-Gvili A
Eur J Intern Med; 2023 Feb; 108():18-24. PubMed ID: 36424271
[TBL] [Abstract][Full Text] [Related]
19. Investigational drugs for immune thrombocytopenia.
Provan D; Newland AC
Expert Opin Investig Drugs; 2022 Jul; 31(7):715-727. PubMed ID: 35531637
[TBL] [Abstract][Full Text] [Related]
20. Real-world impact of primary immune thrombocytopenia and treatment with thrombopoietin receptor agonists on quality of life based on patient-reported experience: Results from a questionnaire conducted in Switzerland, Austria, and Belgium.
Rovó A; Cantoni N; Samii K; Rüfer A; Koenen G; Ivic S; Cavanna D; Benz R
PLoS One; 2022; 17(4):e0267342. PubMed ID: 35446925
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
